Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harvoni in HCV-Associated Chronic Kidney Disease
NCT02503735Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ledipasvir in hepatitis C (HCV), sponsored by Massachusetts General Hospital. Primary endpoint: Percent Change in Proteinuria at 24 weeks. Started Jul 2015; status: terminated.
02
Drugs
ledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02503735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503735.